Bactiguard Holding AB (BACTI.B) AI Stock Analysis

• Market Cap: kr597.50M
• Dividend Yield: N/A
• Average Volume (3M): 77.61K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.24
• Revenue Growth: -8.10%
• EPS Growth: 62.08%
• Country: SE
• Employees: 147
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.21
• Shares Outstanding: 31,043,884
• 10 Day Avg. Volume: 120,571
• 30 Day Avg. Volume: 77,614
• PEG Ratio: 0.53
• Price to Book (P/B): 3.77
• Price to Sales (P/S): 5.08
• P/FCF Ratio: 121.18
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: kr16.50 ▼(-14.51% Downside)

Bactiguard Holding AB's overall stock score is primarily impacted by its financial performance, which is challenged by declining revenues and persistent net losses. Technical analysis indicates a bearish trend, further weighing on the score. Valuation metrics are unattractive due to a negative P/E ratio and lack of dividend yield. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Strong Gross Profit Margin

A high gross profit margin suggests that Bactiguard is effectively managing its production costs, which can support long-term profitability as it scales operations.

Stable Capital Structure

A stable capital structure with a balanced debt-to-equity ratio provides Bactiguard with financial flexibility to invest in growth opportunities and weather economic fluctuations.

Innovative Product Offering

Bactiguard's focus on infection prevention technology positions it well in the healthcare sector, addressing a critical need and offering potential for sustained demand and market expansion.

Negative Factors

Negative Cash Flow Growth

Declining cash flow growth can limit Bactiguard's ability to invest in new projects or expand operations, potentially impacting its long-term growth prospects and financial health.

Declining Revenue Trend

A declining revenue trend indicates challenges in maintaining sales momentum, which could affect Bactiguard's ability to achieve sustainable growth and profitability.

Persistent Losses

Ongoing losses suggest operational inefficiencies and may require strategic adjustments to improve profitability and ensure long-term viability.

Bactiguard Holding AB Business Overview & Revenue Model

Company Description

Bactiguard Holding AB (publ), a medical device company, engages in the development and supply of infection prevention solutions in Sweden and internationally. Its infection prevention solutions reduce the risk of healthcare associated infections and the use of antibiotics. The company's products portfolio of urinary catheters, endotracheal tubes, and central venous catheters reduces the risk of infections in the urinary tract, the respiratory tract, and the bloodstream. Its product portfolio consists of Bactiguard infection protection (BIP) Foley Catheter, an indwelling urinary catheter that reduces microbial adhesion; BIP Central Venous Catheter and BIP Endotracheal Tube, which reduces the risk of biofilm formation and infection; BIP Endotracheal Tube Evac, a tube that combines the subglottic secretion drainage with coating to reduce microbial adhesion; and BIP Foley TempSensor, an indwelling urinary catheter that offers surveillance and infection prevention. The company's products also include Bactiguard Wound Care and Hydrocyn aqua advanced wound care, a wound wash, debridement, and irrigation solution for acute, chronic, and infected wounds; surgical sutures comprise non-absorbable, natural absorbable, synthetic absorbable, and specialty sutures; VigiMesh, a sterile, non-absorbable, and knitted polypropylene monofilament mesh material for tissue reinforcement used in hernia repair; and Hydrocyn aqua advanced disinfectant, a non-alcoholic disinfectant for skin and surfaces to kill bacteria, virus, and fungi. In addition, it offers ZNN Bactiguard, an orthopedic trauma implants with infection prevention technology; and Aniocyn, a wound and skin care products for dogs, cats, horses, and other pets. Bactiguard Holding AB (publ) was founded in 2005 and is headquartered in Tullinge, Sweden.

How the Company Makes Money

Bactiguard generates revenue through the sale of its infection prevention products and coatings to hospitals and healthcare providers worldwide. The company's revenue model is primarily based on direct sales of its medical devices, which incorporate its proprietary Bactiguard coating technology, as well as licensing agreements for its coating technology to third-party manufacturers. Key revenue streams include product sales, royalties from licensing agreements, and potential collaborations with healthcare providers and industry partners aimed at expanding the adoption of its technology. Bactiguard also benefits from strategic partnerships with various healthcare institutions and companies that enhance its market reach and product offerings, contributing significantly to its overall earnings.

Bactiguard Holding AB Financial Statement Overview

Summary

Bactiguard Holding AB faces challenges with declining revenues and persistent losses, as reflected in the negative profit margins and cash flow metrics. While the company maintains a stable capital structure with moderate leverage, the negative return on equity and cash flow issues highlight the need for strategic improvements to enhance profitability and cash generation.

Income Statement

Bactiguard Holding AB shows a declining revenue trend with a negative revenue growth rate of -3.52% in TTM. The company has a strong gross profit margin of 87.8%, indicating efficient cost management. However, the net profit margin is negative at -7.39%, reflecting ongoing losses. The EBIT and EBITDA margins are also negative, suggesting operational challenges.

Balance Sheet

The company's debt-to-equity ratio is moderate at 0.55, indicating a balanced leverage position. However, the return on equity is negative at -5.74%, pointing to inefficiencies in generating returns for shareholders. The equity ratio stands at 55.1%, showing a stable capital structure.

Cash Flow

Bactiguard Holding AB's free cash flow growth rate is significantly negative at -55.62%, indicating declining cash generation. The operating cash flow to net income ratio is 0.18, suggesting limited cash flow relative to net income. The free cash flow to net income ratio is 0.61, showing some ability to cover net losses with free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	221.02M	243.68M	203.99M	223.56M	169.49M	172.31M
Gross Profit	143.92M	207.71M	139.98M	180.14M	130.80M	137.12M
EBITDA	31.71M	24.99M	-89.98M	-543.00K	-5.94M	8.05M
Net Income	-21.27M	-29.82M	-138.38M	-52.88M	-58.77M	-38.39M
Balance Sheet
Total Assets	544.64M	655.91M	662.17M	807.70M	849.29M	675.22M
Cash, Cash Equivalents and Short-Term Investments	37.42M	116.73M	123.22M	197.73M	217.59M	9.89M
Total Debt	166.12M	227.77M	233.10M	238.70M	247.96M	264.02M
Total Liabilities	243.16M	327.57M	309.00M	311.99M	307.84M	301.87M
Stockholders Equity	301.48M	328.34M	353.18M	495.71M	541.45M	373.35M
Cash Flow
Free Cash Flow	-388.00K	10.21M	-60.94M	-7.86M	-38.00K	-14.65M
Operating Cash Flow	5.68M	24.99M	-52.33M	3.06M	7.26M	702.00K
Investing Cash Flow	-6.07M	-14.78M	-8.61M	-10.92M	-7.29M	-57.01M
Financing Cash Flow	-66.63M	-21.20M	-11.84M	-13.89M	205.83M	46.20M

Bactiguard Holding AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 19.30
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BACTI.B, the sentiment is Negative. The current price of 19.3 is above the 20-day moving average (MA) of 18.10, above the 50-day MA of 17.30, and below the 200-day MA of 25.19, indicating a neutral trend. The MACD of 0.18 indicates Positive momentum. The RSI at 47.40 is Neutral, neither overbought nor oversold. The STOCH value of 17.65 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BACTI.B.

Bactiguard Holding AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAD.B	66 Neutral	kr1.10B	47.17	6.93%	―	-5.80%	-65.99%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INTEG.B	48 Neutral	kr282.68M	-7.58	-18.55%	―	0.62%	-82.70%
SEDANA	48 Neutral	kr1.02B	-25.02	-4.42%	―	13.48%	28.98%
BACTI.B	46 Neutral	kr597.50M	-28.08	-6.81%	―	-8.10%	62.08%
SEZI	43 Neutral	kr806.51M	-5.92	-36.55%	―	62.24%	21.16%

Bactiguard Holding AB Corporate Events

Bactiguard Revises Zimmer Biomet Trauma Deal and Recaptures Global Rights Outside Key Markets

Bactiguard has revised its trauma license agreement with orthopedic specialist Zimmer Biomet, granting the US group non-exclusive rights to continue commercializing the ZNN Bactiguard-coated trauma nail system in Europe, selected markets in the Middle East and Africa, and Japan, while Bactiguard regains the remaining global rights in the trauma segment. Under the new structure, Bactiguard will keep earning royalties on actual net sales and introduce a quarterly fixed fee that on an annual basis represents at least half of the previous minimum royalty level, with the company stating that the arrangement will not negatively affect 2025 financials or alter its 2030 strategic and financial targets, thereby preserving earnings visibility while potentially giving it greater strategic flexibility over its infection-prevention trauma portfolio in unlicensed markets.

The most recent analyst rating on ($SE:BACTI.B) stock is a Hold with a SEK16.50 price target. To see the full list of analyst forecasts on Bactiguard Holding AB stock, see the SE:BACTI.B Stock Forecast page.

Bactiguard Appoints Nomination Committee for 2026 AGM

Bactiguard Holding AB has appointed its Nomination Committee for the upcoming Annual General Meeting in 2026, scheduled for May 19 in Stockholm. The committee, comprising representatives from major shareholders, will propose candidates for the Board of Directors and auditors, as well as remuneration policies. This appointment is a routine part of Bactiguard’s governance structure, ensuring shareholder involvement in key decisions and maintaining transparency in its operations.

The most recent analyst rating on ($SE:BACTI.B) stock is a Hold with a SEK17.50 price target. To see the full list of analyst forecasts on Bactiguard Holding AB stock, see the SE:BACTI.B Stock Forecast page.

Bactiguard Reports Revenue Decline but Maintains Profitability in Q3 2025

Bactiguard Holding AB reported a decrease in revenue and net sales for the third quarter of 2025, with total revenue dropping by 34.5% and net sales by 32.5% compared to the previous year. Despite the decline, the company maintained profitability with an EBITDA of SEK 5.3 million, attributing the lower figures to a weaker USD and a high base from the previous year. The company continues to see growth in its Hydrocyn aqua product, although there was a decline in sutures. The report highlights ongoing challenges but also underscores the company’s commitment to future growth through clinical evidence and strategic focus areas.

The most recent analyst rating on ($SE:BACTI.B) stock is a Hold with a SEK25.00 price target. To see the full list of analyst forecasts on Bactiguard Holding AB stock, see the SE:BACTI.B Stock Forecast page.